Wake Forest University Health Sciences
This Registry study will prospectively evaluate the differences in treatment outcomes in terms of pain intensity, pain interference, concomitant medication use, health-related quality of life, opioid adverse effects, and healthcare utilization between targeted drug delivery and conservative medication management only groups.
Cancer Pain
Chronic Pain
Cancer Associated Pain
Neuropathic Pain
Intrathecal Targeted Drug Delivery
Conservative medical management
This is a prospective, open-label, short term patient registry where up to 169 subjects with cancer associated pain will be enrolled. Subjects with cancer associated pain who are receiving conservative medical management (CMM) only and cancer patients receiving Intrathecal Drug Delivery system (IDDs) along with CMM will be followed for up to 3 months. Subjects will be evaluated monthly up to 3 months from the medical care initiation which is the implant day for the IDDs group and start of the new treatment plan for the CMM group. Subjects that decide to cross-over to the IDDs group in a future date, will still be followed for their progress. Based on routine care, subjects will be seen at day of implant, 1 month post-implant, 2 months post-implant, and 3- and 6- months post-implant.
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 169 participants |
| Official Title : | Intrathecal Targeted Drug Delivery for Cancer Associated Pain |
| Actual Study Start Date : | 2022-12-06 |
| Estimated Primary Completion Date : | 2025-06-30 |
| Estimated Study Completion Date : | 2025-12-06 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 21 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Advocate Aurora Health
Oshkosh, Wisconsin, United States, 54904